Vitamin D3 for Life

Live Enlightened

Research libraryVitamin D3 For Life
Study design and methods

Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

Why this paper is included

Supporting source evidence:

Individuals who experienced CVD mortality differed significantly from those alive or with non-CVD mortality with respect to age, sex, BMI, blood pressure, sleep disorder, mobility difficulty, CHF, MI, CKD and CKD stage, asthma, anemia, lymphocyte, monocyte and neutrophil (NEUT), red cell count, urinary albumin-to-creatinine ratio, urinary protein, blood urea nitrogen (BUN), uric acid (UA), serum creatinine, eGFR, alanine aminotransferase, globulin, calcium, potassium, and vitamin D (P < .05; Table 1).

Source: 3.1. Baseline characteristics of participants. View original paper

Relevance classification does not establish study quality, causation or editorial approval.

Study design Study design awaiting verification.

Study design awaiting verification

The available source does not establish a sufficiently clear study design.

Meta-analysis unclear · Blinding unclear / not reported · Human research reported

How this paper was classified

Automatic source-based classification; awaiting editorial verification. This is not a quality score.

After initial pooling, 1,01,316 participants were screened.

Source: Methods.

View supporting evidence in the original paper

What the study types mean
Systematic review
Uses explicit methods to identify, assess and summarise research on a defined question.
Scoping review
Maps the extent and characteristics of research on a topic.
Narrative review
Discusses existing research; systematic-review methods have not been established by this classification.
Review / evidence synthesis
Reviews existing research; the exact review methods need further assessment.
Randomised controlled trial
Assigns participants or groups to comparison interventions by chance.
Non-randomised intervention study
Examines an intervention without random allocation.
Cohort study
Examines exposures and outcomes over time within a defined group.
Case-control study
Compares people with an outcome against people without it, examining exposures.
Cross-sectional study
Examines a population at a particular point in time.
Observational study
Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
Case report
Describes an individual case.
Case series
Describes a group of individual cases.
Secondary analysis
Analyses existing study data; this paper is not automatically another independent trial.
Laboratory study
Investigates biological processes in a laboratory setting.
Qualitative study
Examines experiences or meanings using qualitative methods.
Genetic instrumental-variable study
Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
Study protocol
Describes planned methods and is not evidence that the planned study has reported results.
Multiple reported designs
More than one design is explicitly reported; examine the supporting methods.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.

Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.

Abstracts

Machine learning based predictive model for cardiovascular disease mortality risk in patients with stage 4 cardiovascular-kidney-metabolic syndrome

Study design awaiting verification · Medicine · 2026

Original publication title

Machine learning based predictive model for cardiovascular disease mortality risk in patients with stage 4 cardiovascular: kidney: metabolic syndrome

Pengyu Zhang; Sining Wang; He Yang; Yixin He; Zhihui Xu; Taijin Wu; Zhouyu Su; Weizhe Deng; Qiang Zhang

Copyright © 2026 the Author(s). Published by Wolters Kluwer Health, LLC.

Original publication · Publisher record · CC BY 4.0

Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.

At a glance

What does the authors’ abstract report?

Patients with stage 4 cardiovascular: kidney: metabolic (CKM) syndrome are exposed to an elevated cardiovascular disease (CVD) mortality risk. However, large-sample, multidimensional prediction models for CVD mortality risk that integrate clinical indicators, as well as highly applicable supporting tools, remain lacking. A total of 2893 patients with stage 4 CKM were randomly allocated to training and validation sets at a 7:3 ratio. The prediction model was constructed via variable screening using least absolute shrinkage and selection operator combined with multivariate Cox regression.

Discrimination, calibration, and clinical utility of the model were evaluated with receiver operating characteristic curves, calibration plots, and decision curve analysis. A nomogram and web-based calculator were constructed. Six machine learning models were used to validate the model, and predictive factors were identified via SHapley Additive exPlanations analysis. Nine risk factors were ultimately identified for constructing the predictive model: age, gender, mobility difficulty, chronic kidney disease, anemia, neutrophil, blood urea nitrogen, albumin, and C-reactive protein. The model’s discriminate ability on training set (C-index = 0.773) was comparable that on validation set (C-index = 0.779).

Additionally, the model exhibited optimal performance in predicting 15-year CVD mortality (area under the curve = 0.871). The calibration curve demonstrated comparable fit, and decision curve analysis revealed that the nomogram score provided higher clinical benefit compared with any single variable. Participants with high nomogram scores exhibited a lower survival rate (log-rank test, P < .001). Among the 6 machine learning models, Random Forest and XGBoost achieved the best performance. SHapley Additive exPlanations analysis further indicated that age and C-reactive protein made the greatest contributions to predicting CVD mortality risk.

The CVD mortality risk prediction model developed for patients with stage 4 CKM demonstrated robust performance. This model may enable clinicians to identify high-risk patients early and to formulate individualized intervention strategies through a reliable decision support tool.

Authors’ abstract

Patients with stage 4 cardiovascular: kidney: metabolic (CKM) syndrome are exposed to an elevated cardiovascular disease (CVD) mortality risk. However, large-sample, multidimensional prediction models for CVD mortality risk that integrate clinical indicators, as well as highly applicable supporting tools, remain lacking. A total of 2893 patients with stage 4 CKM were randomly allocated to training and validation sets at a 7:3 ratio. The prediction model was constructed via variable screening using least absolute shrinkage and selection operator combined with multivariate Cox regression.

Discrimination, calibration, and clinical utility of the model were evaluated with receiver operating characteristic curves, calibration plots, and decision curve analysis. A nomogram and web-based calculator were constructed. Six machine learning models were used to validate the model, and predictive factors were identified via SHapley Additive exPlanations analysis. Nine risk factors were ultimately identified for constructing the predictive model: age, gender, mobility difficulty, chronic kidney disease, anemia, neutrophil, blood urea nitrogen, albumin, and C-reactive protein. The model’s discriminate ability on training set (C-index = 0.773) was comparable that on validation set (C-index = 0.779).

Additionally, the model exhibited optimal performance in predicting 15-year CVD mortality (area under the curve = 0.871). The calibration curve demonstrated comparable fit, and decision curve analysis revealed that the nomogram score provided higher clinical benefit compared with any single variable. Participants with high nomogram scores exhibited a lower survival rate (log-rank test, P < .001). Among the 6 machine learning models, Random Forest and XGBoost achieved the best performance. SHapley Additive exPlanations analysis further indicated that age and C-reactive protein made the greatest contributions to predicting CVD mortality risk.

The CVD mortality risk prediction model developed for patients with stage 4 CKM demonstrated robust performance. This model may enable clinicians to identify high-risk patients early and to formulate individualized intervention strategies through a reliable decision support tool.

Publication and source details

Original title: Machine learning based predictive model for cardiovascular disease mortality risk in patients with stage 4 cardiovascular: kidney: metabolic syndrome

Pengyu Zhang; Sining Wang; He Yang; Yixin He; Zhihui Xu; Taijin Wu; Zhouyu Su; Weizhe Deng; Qiang Zhang

Medicine · 2026

* Correspondence: Qiang Zhang, Department of Rheumatology and Chinese Medicine, The 962nd Hospital of the PLA, No. 45, Xuefu Road, Nangang District, Harbin 150080, China (e-mail: zhangqiang@hrbipe.edu.cn).Copyright © 2026 the Author(s). Published by Wolters Kluwer Health, LLC.2026https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Repository JATS snapshot; version as supplied

Source retrieved: 2026-11-10T21:35:30.926820+00:00

DOI: 10.1097/md.0000000000051266 · PMC13706199